M&A trends in AI for drug discovery
Advances in AI promise to transform drug discovery and development. AI not only brings more efficiency to today’s costly and slow processes but also holds the potential to identify entirely
Advances in AI promise to transform drug discovery and development. AI not only brings more efficiency to today’s costly and slow processes but also holds the potential to identify entirely
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need and with a lack of treatment alternatives, has announced
Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma,
Background Cytokine Release Syndrome (CRS) is a well-recognized toxicity that occurs with high frequency following treatments such as T-cell engaging antibodies, Chimeric Antigen Receptor (CAR) T cells and other T-cell
Artificial intelligence (AI) has emerged as a promising solution with significant potential to revolutionize drug discovery and development. The global AI in healthcare market, valued at USD 16.3 billion in
Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is
Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker
Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Japanese Patent Office
Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs. It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that an abstract highlighting the potential of